Signet Healthcare Partners’ Investment in Goodwin Biotechnology

Fairmount Partners LP served as financial advisor for Goodwin. Pepper Hamilton LLP acted as legal counsel for Goodwin and Sheppard, Mullin, Richter & Hampton LLP acted as legal counsel for Signet Healthcare Partners.

Goodwin Biotechnology, Inc. has completed its largest ever round of financing with growth capital which will help fund its next stage of expansion. Goodwin is a full GMP, FDA-registered biopharmaceuticals Contract Development and Manufacturing Organization (CDMO) that offers a fully integrated Single Source Solution™ from Cell Line Development, Process Development including Bioconjugation, Scale-Up, cGMP Contract Manufacturing and Aseptic Fill/Finish of mammalian cell-culture derived life-saving monoclonal antibodies, recombinant proteins, vaccines, and Antibody Drug Conjugates (ADCs). The investment was made by Signet Healthcare Partners (“Signet”), a New York based growth equity firm specializing in healthcare investments.

Concurrently, Nikhil Puri and Jerry Liao, investors at Signet, will join the board of directors of Goodwin Biotechnology. The growth capital will be used to support Goodwin’s investments in doubling its space available for cGMP capacity as it readies for further expansion of its biopharmaceutical manufacturing, including support for commercial product manufacturing and developing various capabilities to better serve its growing customer base.

Sheppard Mullin represented Signet Healthcare Partners with a team led by partner Shon Glusky (Picture), included special Counsel Farha Chowdry and Carol Archer; and attorney Nathaniel Schlakman.

Involved fees earner: Carol Archer Boboris – Sheppard Mullin; Farha Chowdry – Sheppard Mullin; Shon Glusky – Sheppard Mullin;

Law Firms: Sheppard Mullin;

Clients: Signet Healthcare Partners;


Author: Ambrogio Visconti